

## Special Issue

# Epigenetics and Immune Checkpoints

### Message from the Guest Editors

The epigenetic immune modeling of cancer cells represents a key hallmark of cancer, as it impairs the host's functional immune recognition of malignant cells. The pharmacologic targeting of epigenetic alteration with epigenetic drugs has been demonstrated to possess significant immunomodulatory properties, sensitizing tumor cells to emerging immunotherapies.

It is essential to identify new mechanism(s) underlying treatment failure(s) and design novel epigenetic-based combination therapeutic approaches to overcome primary/secondary resistance. In addition, novel biomarkers for the prediction of the response to immune-checkpoint inhibitors are urgently needed to stratify cancer patients who would benefit most from this treatment. In this context, epigenetic biomarkers would represent a valuable tool to predict response to immunotherapy, thus offering more personalized therapeutic regimens. Therefore, our aim is to present a collection of the latest research regarding the role that epigenetics plays in improving cancer immunotherapy, and the utility in defining potential therapeutic targets and cancer biomarkers.

---

### Guest Editors

Dr. Alessia Covre

Center for Immuno-Oncology, Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena and University of Siena, Siena, Italy.

Dr. Elisabetta Fratta

Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico, Aviano, Italy

---

### Deadline for manuscript submissions

closed (31 May 2022)



## Epigenomes

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 4.4  
Indexed in PubMed



[mdpi.com/si/68055](https://mdpi.com/si/68055)

*Epigenomes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[epigenomes@mdpi.com](mailto:epigenomes@mdpi.com)

[mdpi.com/journal/  
epigenomes](https://mdpi.com/journal/epigenomes)





# Epigenomes

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 4.4  
Indexed in PubMed



[mdpi.com/journal/  
epigenomes](https://mdpi.com/journal/epigenomes)



## About the Journal

### Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

*Epigenomes* (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

---

### Editor-in-Chief

Prof. Dr. Ernesto Guccione

Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, NY 10029, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, PubAg, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Biochemistry, Genetics and Molecular Biology (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25.5 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the second half of 2025).